Bilihome key facts
as of Oct 2026- Developer of wearable phototherapy technology designed to treat jaundice in newborn babies.
- Bilihome is valued at approximately $11.7M as of Oct 2026 (last reported valuation).
- It has raised $2.7M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Oost NL, NLC Health Ventures, Health Innovations.
- Status: Privately Held (backing).
Bilihome's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·Watch Bilihome: the Monday email on marks, rounds and moves
Bilihome funding rounds
No funding rounds for Bilihome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Bilihome
3Bilihome valuation
Bilihome's last reported valuation was $11.7 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Bilihome investors
3 investors are on record for Bilihome, including Oost NL, NLC Health Ventures and Health Innovations.
About Bilihome
Developer of wearable phototherapy technology designed to treat jaundice in newborn babies. The company's technology specializes in avoiding light leakage and allows breathability to fine-tune the light distribution, and can be worn by the baby during breastfeeding, having skin-to-skin contact, and even when the baby is carried around, enabling parents to avoid phototherapy in NICU and treat jaundice.
- Sector
- Healthcare
- HQ
- Nijkerk, Netherlands
- Founded
- 2019
- Employees
- 7
- Website
- bilihome.org/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.